Concepedia

Publication | Open Access

Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria

DOIFull Paper Access

631

Citations

23

References

2004

Year

Peter Hillmen, Claire Hall, Judith Marsh, Modupe Elebute, Michael P. Bombara, Beth E. Petro, Matthew Cullen, Stephen J. Richards, Scott A. Rollins, Christopher F. Mojcik,
New England Journal of Medicine

Abstract

Eculizumab is safe and well tolerated in patients with PNH. This antibody against terminal complement protein C5 reduces intravascular hemolysis, hemoglobinuria, and the need for transfusion, with an associated improvement in the quality of life in patients with PNH.

References

YearCitations

Page 1